- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04513912
Un estudio de Seltorexant en comparación con quetiapina XR como terapia complementaria a los antidepresivos en participantes adultos y ancianos con trastorno depresivo mayor con síntomas de insomnio que han respondido de manera inadecuada a la terapia antidepresiva
Estudio de grupos paralelos, aleatorizado, doble ciego con quetiapina de liberación prolongada como comparador para evaluar la eficacia y la seguridad de seltorexant 20 mg como terapia adyuvante a los antidepresivos en pacientes adultos y ancianos con trastorno depresivo mayor con síntomas de insomnio que han respondido inadecuadamente a la terapia antidepresiva
The purpose of this study is to assess the efficacy of seltorexant compared with quetiapine extended-release (XR) as adjunctive therapy to an antidepressant drug in treatment response in participants with major depressive disorder with insomnia symptoms (MDDIS) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Major depressive disorder (MDD) is a common, serious, recurrent disorder. Seltorexant (JNJ-42847922) is a potent and selective antagonist of the human orexin-2 receptor (OX2R) that is being developed for the adjunctive treatment of MDDIS. The hypothesis for this study is that seltorexant is superior to quetiapine XR in leading to a response after 26 weeks of treatment (greater than or equal to [>=] 50 percent [%] improvement on baseline Montgomery Asberg Depression Rating Scale [MADRS] total score), when administered as adjunctive treatment to an antidepressant in adult and elderly participants with MDDIS who have had an inadequate response to treatment with an SSRI/SNRI. The study will be conducted in 3 phases: a screening phase (up to 30 days), a double-blind (DB) treatment phase (26 weeks), and a post treatment follow-up phase (7 to 14 days after the end of DB treatment phase for all participants, and up to 196 days from baseline for participants who stop study treatment early). The total study duration for each participant will be approximately 32 weeks. Efficacy, safety, pharmacokinetics, and biomarkers will be assessed at specified time points during this study.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Buenos Aires, Argentina, 1058AAJ
- CENydET - Centro Neurobiologico y de Stress Traumatico
-
Buenos Aires, Argentina, C1405BOA
- FunDaMos
-
Buenos Aires, Argentina, 1199
- Hospital Italiano
-
Ciudad Autonoma Buenos Aires, Argentina, C1428AQK
- Hospital Fleni
-
Córdoba, Argentina, X5004AOA
- Instituto Privado Kremer
-
Córdoba, Argentina, 5000
- Fundacion Lennox
-
Córdoba, Argentina, X5006IKK
- Centro Medico Luquez
-
La Plata, Argentina, Thanks
- Clinica Privada de Salud Mental Santa Teresa de Ávila
-
La Plata, Argentina, 1902
- CENPIA
-
Mendoza, Argentina, M5502AWY
- CENAIN
-
San Miguel de Tucumán, Argentina, 4000
- Clinica Mayo de UMCB
-
-
-
-
-
Pleven, Bulgaria, 5800
- Medical Center Medconsult-Pleven
-
Plovdiv, Bulgaria, 4028
- MC 'Hipokrat - N', EOOD
-
Rousse, Bulgaria, 7003
- Mental Health Center - Rousse
-
Sofia, Bulgaria, 1680
- Medical Center Intermedica, OOD
-
Sofia, Bulgaria, 1113
- Medical Center St. Naum
-
Sofia, Bulgaria, 1784
- MC 'Synexus Sofia' EOOD
-
Stara Zagora, Bulgaria, 6003
- UMHAT Prof. Dr. St. Kirkovich AD
-
Stara Zagora, Bulgaria, 6000
- MC 'Synexus Sofia' EOOD
-
Tzarev Brod, Bulgaria, 9747
- State Psychiatric Hospital - Tzarev Brod
-
Varna, Bulgaria, 9020
- Diagnostic Consulting Center Mladost - M Varna
-
Veliko Tarnovo, Bulgaria, 5000
- Mental Health Center - Veliko Tarnovo EOOD
-
-
-
-
-
Bruges, Bélgica, 8310
- AZ Sint-Lucas
-
Sint-Niklaas, Bélgica, 9100
- AZ Nikolaas
-
-
-
-
Nova Scotia
-
Sydney, Nova Scotia, Canadá, B1P 1E1
- A.K. Munshi Medical Inc.
-
-
Ontario
-
Toronto, Ontario, Canadá, M3J 2C5
- Canadian Phase Onward
-
-
Quebec
-
Montreal, Quebec, Canadá, H1M 1B1
- Clinique Force Medic (GCP Trials)
-
-
-
-
-
Brno, Chequia, 60200
- Psychiatricka ambulance Saint Anne s.r.o.
-
Hradec Králové, Chequia, 500 09
- NeuropsychiatrieHK, s.r.o.
-
Pilsen, Chequia, 301 00
- A Shine S R O
-
Prague, Chequia, 100 00
- Clintrial s r o
-
Prague, Chequia, 160 00
- NeuropsychiatrieHK, s.r.o.
-
Prague, Chequia, 10000
- AD71 s.r.o.
-
Prague, Chequia, 186 00
- Institut Neuropsychiatricke pece
-
-
-
-
-
Banská Bystrica, Eslovaquia, 97401
- Psychomed-Svatosavsky, s.r.o.
-
Bojnice, Eslovaquia, 97201
- Nemocnica s poliklinikou Prievidza so sidlom v Bojniciach
-
Košice, Eslovaquia, 040 11
- Epamed sro
-
Liptovský Mikuláš, Eslovaquia, 03123
- Liptovska Nemocnica S Poliklinikou Mudr. Ivana Stodolu
-
Rimavská Sobota, Eslovaquia, 97901
- Psychiatricka Ambulancia Psycholine S.R.O.
-
Trenčín, Eslovaquia, 91101
- FN Trencin
-
Trenčín, Eslovaquia, 91108
- Pro mente sana s.r.o.
-
Žilina, Eslovaquia, 1207
- Fakultna nemocnica s poliklinikou v Ziline
-
-
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35233
- University of Alabama at Birmingham
-
-
Arizona
-
Tucson, Arizona, Estados Unidos, 85712
- SW Biomedical Research LLC
-
-
California
-
Culver City, California, Estados Unidos, 90230
- Proscience Research Group
-
Encino, California, Estados Unidos, 91316
- Pharmacology Research Institute
-
Garden Grove, California, Estados Unidos, 92845
- Collaborative NeuroScience Network
-
Long Beach, California, Estados Unidos, 90806
- Collaborative NeuroScience Network
-
Los Alamitos, California, Estados Unidos, 90720
- Pharmacology Research Institute
-
Los Angeles, California, Estados Unidos, 90025
- CalNeuro Research
-
Newport Beach, California, Estados Unidos, 92660
- Pharmacology Research Institute
-
Orange, California, Estados Unidos, 92868
- NRC Research Institute
-
Orange, California, Estados Unidos, 92868
- Pacific Neuropsychiatric Specialists
-
Pico Rivera, California, Estados Unidos, 90660
- CNRI-Los Angeles, LLC
-
Rancho Cucamonga, California, Estados Unidos, 91730
- Prospective Research Innovations Inc
-
Redlands, California, Estados Unidos, 92374
- Anderson Clinical Research
-
San Diego, California, Estados Unidos, 92103
- University of California at San Diego
-
Santa Ana, California, Estados Unidos, 92705
- CI Trials
-
Santa Ana, California, Estados Unidos, 91704
- National Research Institute
-
Santee, California, Estados Unidos, 92071
- CMB Clinical Trials
-
Sherman Oaks, California, Estados Unidos, 91403
- Schuster Medical Research Institute
-
Upland, California, Estados Unidos, 91786
- Pacific Clinical Research Medical Group
-
-
Connecticut
-
Hartford, Connecticut, Estados Unidos, 06102
- Hartford Hospital
-
-
Florida
-
Doral, Florida, Estados Unidos, 33166
- Moonshine Research Center, Inc
-
Hallandale, Florida, Estados Unidos, 33009
- Velocity Clinical Research, Hallandale Beach
-
Hialeah, Florida, Estados Unidos, 33012
- Indago Research & Health Center Inc
-
Hialeah, Florida, Estados Unidos, 33012
- New Life Medical Research Center, Inc.
-
Hialeah, Florida, Estados Unidos, 33013
- Amedica Research Institute Inc
-
Lakeland, Florida, Estados Unidos, 33803
- Meridien Research
-
Miami, Florida, Estados Unidos, 33122
- Premier Clinical Research
-
Miami, Florida, Estados Unidos, 33125
- Global Medical Institutes
-
Miami, Florida, Estados Unidos, 33137
- Miami Jewish Health System
-
Orlando, Florida, Estados Unidos, 32806
- Synexus Research Orlando
-
Orlando, Florida, Estados Unidos, 23801
- Clinical Neuroscience Solutions
-
Tampa, Florida, Estados Unidos, 33612
- University of South Florida
-
The Villages, Florida, Estados Unidos, 32162
- Compass Research LLC-Bioclinica Research
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30331
- Atlanta Center for Medical Research
-
Atlanta, Georgia, Estados Unidos, 30328
- Synexus Clinical Research US Inc
-
Decatur, Georgia, Estados Unidos, 30030
- iResearch Atlanta LLC
-
Marietta, Georgia, Estados Unidos, 30060
- Psych Atlanta, P.C.
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60634
- Chicago Research Center
-
Libertyville, Illinois, Estados Unidos, 60048
- Capstone Clinical Research
-
Lisle, Illinois, Estados Unidos, 60532
- Alexian Brothers Health System
-
Naperville, Illinois, Estados Unidos, 60563
- Baber Research Group
-
Oakbrook Terrace, Illinois, Estados Unidos, 60618
- Lemah Creek Clinical Research
-
-
Kansas
-
Wichita, Kansas, Estados Unidos, 67214
- Ascension via Christi Research
-
-
Louisiana
-
New Orleans, Louisiana, Estados Unidos, 70115
- Riverstar Research
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21208
- Pharmasite Research, Inc.
-
-
Massachusetts
-
New Bedford, Massachusetts, Estados Unidos, 02740
- BTC of New Bedford
-
Roslindale, Massachusetts, Estados Unidos, 02135
- Boston Clinical Trials & Medical Research
-
-
Missouri
-
O'Fallon, Missouri, Estados Unidos, 63368
- Psychiatric Care and Research Center (PCRC)
-
-
New Jersey
-
Toms River, New Jersey, Estados Unidos, 08755
- Bio Behavioral Health
-
-
New York
-
Brooklyn, New York, Estados Unidos, 11235
- SPRI Clinical Trials, LLC
-
New York, New York, Estados Unidos, 10128
- The Medical Research Network, LLC
-
New York, New York, Estados Unidos, 10017
- Fieve Clinical Research Inc
-
Rochester, New York, Estados Unidos, 14618 1609
- Finger Lakes Clinical Research
-
Staten Island, New York, Estados Unidos, 10312
- Richmond Behavioral Associates
-
-
North Carolina
-
Durham, North Carolina, Estados Unidos, 27701
- Velocity Clinical Research, Inc.
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45219
- University of Cincinnati, Dept of Psychiatry & Behavioral Neuroscience
-
Dayton, Ohio, Estados Unidos, 45417
- Midwest Clinical Research Center
-
North Canton, Ohio, Estados Unidos, 44720
- Neuro Behavioral Clinical Research
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73112
- Sooner Clinical Research
-
Oklahoma City, Oklahoma, Estados Unidos, 73118
- Paradigm Research Professionals, LLC
-
-
Pennsylvania
-
Pine Hill, Pennsylvania, Estados Unidos, 08021
- Suburban Research Associates
-
Scranton, Pennsylvania, Estados Unidos, 18503
- Global Medical Institutes
-
-
South Carolina
-
Mt. Pleasant, South Carolina, Estados Unidos, 29464
- Coastal Carolina Research Center
-
-
Texas
-
Bellaire, Texas, Estados Unidos, 77401
- West Houston Clinical Research Service
-
Fort Worth, Texas, Estados Unidos, 76104
- North Texas Clinical Trials
-
Mansfield, Texas, Estados Unidos, 76054
- Hawkins Psychiatry, PC
-
The Woodlands, Texas, Estados Unidos, 77381
- Family Psychiatry of The Woodlands
-
Wichita Falls, Texas, Estados Unidos, 76309
- Grayline Research Center
-
-
Utah
-
Clinton, Utah, Estados Unidos, 84015
- Alpine Research Organization
-
Draper, Utah, Estados Unidos, 84020
- Cedar Clinical Research
-
-
Virginia
-
Charlottesville, Virginia, Estados Unidos, 22903
- University of Virginia
-
-
Washington
-
Bellevue, Washington, Estados Unidos, 98007
- Northwest Clinical Research Center
-
Everett, Washington, Estados Unidos, 98201
- Core Clinical Research
-
-
Wisconsin
-
Waukesha, Wisconsin, Estados Unidos, 53188
- Cary J. Kohlenberg, MD, SC, dba, IPC Research.
-
-
-
-
-
Jelgava, Letonia, LV-3008
- The Mental Hospital of Jelgava Ģintermuiža - Psychiatry
-
Liepāja, Letonia, LV-3401
- L. Keruze Practice in Psychiatry
-
Outpatient Centre of Psychiatry, Letonia, LV-4601
- Hospital of Rezekne
-
Riga, Letonia, LV-1002
- Riga Centre of Psychiatry and Narcology
-
-
-
-
-
Kaunas, Lituania, 48259
- Kaunas Silainiu Outpatient Clinic, Public Institution
-
Kaunas, Lituania, 53136
- Republic Kaunas Hospital
-
Kaunas, Lituania, LT-44279
- Romuvos Klinika, JSC
-
Kaunas, Lituania, LT-50009
- Hospital of Lithuanian University of Health Sciences Kaunas Clinics
-
Vilnius, Lituania, 09112
- Zirmunai Mental Health Center, Public Institution
-
Vilnius, Lituania, 10309
- Vilnius Mental Health Center
-
Vilnius, Lituania, 10204
- Antakalnis Psychiatric Consultation Centre, Public Institution
-
Šilutė, Lituania, 99176
- Medical Center Puriena JSC
-
-
-
-
-
Ipoh, Malasia, 30990
- Hospital Raja Permaisuri Bainun
-
Johor Bahru, Malasia, 81200
- Hospital Permai
-
Pulau Pinang, Malasia, 10990
- Hospital Pulau Pinang
-
Seremban, Malasia, 70300
- Hospital Tuanku Jaafar
-
-
-
-
-
Bełchatów, Polonia, 97-400
- Gabinet Lekarski Psychiatryczny Ireneusz Kaczorowski
-
Bialystok, Polonia, 15-464
- Wlokiennicza MED Specjalistyczna Praktyka Lekarska dr n.med. Tomasz Markowski
-
Bydgoszcz, Polonia, 85-080
- Przychodnia Srodmiescie SP. z o.o.
-
Gdansk, Polonia, 80 546
- Centrum Badan Klinicznych PI House sp z o o
-
Lodz, Polonia, 90-009
- Specjalistyczna Indywidualna Praktyka Lekarska
-
Lodz, Polonia, 90-368
- CCBR - Lodz - PL
-
Lublin, Polonia, 20-582
- Specjalistyczna Praktyka Lekarska Marek Domanski
-
Poznan, Polonia, 60-702
- Synexus Polska Sp. z.o.o. Oddzial w Poznaniu
-
Warsaw, Polonia, 01 737
- Specjalistyczny Osrodek Medycyny Wieku Dojrzalego Sp z o.o.
-
Warsaw, Polonia, 02 957
- Instytut Psychiatrii I Neurologii
-
-
-
-
-
Derby, Reino Unido, DE22 3LZ
- Kingsway Hospital
-
Greater Manchester, Reino Unido, M15 6SX
- Synexus
-
Harrogate, Reino Unido, HG1 2PW
- Garden Valleys Resource Centre
-
London, Reino Unido, SE5 8EF
- Kings College Hospital NHS Trust
-
Redruth, Reino Unido, TR15 2SP
- Cornwall Partnership Foundation Trust
-
-
-
-
-
Engel's, Rusia, 413124
- Engels psychiatric hospital
-
Kemerovo, Rusia, 650036
- Kemerovo Regional Clinical Psychiatric Hospital
-
Lipetsk Region, Rusia, 399313
- GUZ Lipetsk Regional psychoneurological Hospital #1
-
Moscow, Rusia, 105082
- JSC Scientific Centre of Personalized Medicine
-
Moscow, Rusia, 107076
- FSI Moscow SRI of Psychiatry of Minzdravsocrazvitia
-
Moscow, Rusia, 107076
- Moscow Scientific Research Institute of Psychiatry
-
Omsk, Rusia, 644070
- Clinical Psychiatry Hospital n.a. N.N. Solodovnikov
-
Saint Petersburg, Rusia, 192019
- St-Petersburg Bekhterev Psychoneurological Research Institute
-
Tomsk, Rusia, 634009
- Klinika StoLet Ltd
-
Yekaterinburg, Rusia, 620030
- Sverdlov Regional Psychiatric Clinical Hospital
-
-
-
-
-
Belgrade, Serbia, 11000
- University Clinical Center of Serbia
-
Belgrade, Serbia, 11000
- General Hospital Euromedik
-
Belgrade, Serbia, 11000
- University Clinical Hospital Center Dr Dragisa Misovic- Dedi
-
Belgrade, Serbia, 11000
- General Hospital Acibadem Bel Medic
-
Belgrade, Serbia, 11000
- Institute of Mental Health Serbia
-
Kovin, Serbia, 26220
- Special Neuropsychiatric Hospital Kovin
-
Kragujevac, Serbia, 34000
- University Clinical Center Kragujevac
-
Niš, Serbia, 18000
- Clinical Center Nis
-
Novi Kneževac, Serbia, 23330
- Specialized Hospital for Neuropsychiatric Diseases Sveti Vracevi
-
-
-
-
-
Hlevakha, Ucrania, 8631
- MNCE of Kyiv RC Regional Psychiatric and Narcological Medical Association
-
Kharkiv, Ucrania, 61068
- Mnpe of Kharkiv Regional Council 'Regional Clinical Psychiatric Hospital #3'
-
Kyiv, Ucrania, 04080
- Kyiv Territorial Medical Incorporation 'Psychiatry'
-
Kyiv, Ucrania, 1030
- Railway Clinical Hospital #1 of Kiev Railway station of DTGO 'South-Western Railway'
-
Kyiv, Ucrania, 1034
- Medical Center Health and Happy
-
Nove, Ucrania, 25491
- Mnpe 'Regional Clinical Psychiatric Hospital of Kirovohrad Regional Council'
-
Ternopil, Ucrania, 46020
- Ternopil RCCPH Depts of Psychiatry #2 (m) & Psychiatry #4 (f) Ternopil I.Ya. Gorbachevskyi SMU
-
Zaporizhzhya, Ucrania, 69600
- Zaporizhzhia Regional Clinical Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Meet diagnostic and statistical manual of mental disorders-5th edition (DSM-5) diagnostic criteria for major depressive disorder (MDD), without psychotic features, based upon clinical assessment and confirmed by the structured clinical interview for DSM-5 Axis I disorders-clinical trials version (SCID-CT) diagnosed with first depressive episode prior to age 60. The length of the current depressive episode must be less than or equal to (<=) 24 months
- Have had an inadequate response to at least 1 but no more than 2 antidepressants, administered at an adequate dose and duration in the current episode of depression. The current antidepressant cannot be the first antidepressant treatment for the first lifetime episode of depression. An inadequate response is defined as less than (<) 50 percent (%) reduction but with some improvement (that is, improvement greater than [>] 0%) in depressive symptom severity with residual symptoms present other than insomnia, and overall good tolerability, as assessed by the Massachusetts General Hospital-Antidepressant Treatment Response Questionnaire (MGH-ATRQ)
- Is receiving and tolerating well any one of the following selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) for depressive symptoms at screening, in any formulation and available in the participating country: citalopram, duloxetine, escitalopram, fluvoxamine, fluoxetine, milnacipran, levomilnacipran, paroxetine, sertraline, venlafaxine, desvenlafaxine, vilazodone, or vortioxetine at a stable dose (at or above therapeutic dose level) for at least 6 weeks, and for no greater than 18 months in the current episode
- Have a hamilton depression rating scale (HDRS)-17 total score greater than or equal to (>=) 20 at the first screening interview, must not demonstrate a clinically significant improvement (that is, an improvement of > 20% on their HDRS-17 total score) from the first to the second independent HDRS-17 rating, and must have a HDRS-17 total score >18 at the second screening interview
- Have a patient version insomnia severity index (ISI) total score >= 15 as well as a clinician version of the ISI total score >= 15 at the second screening visit
- Body mass index (BMI) between 18 and 40 kilogram per meter square (kg/m^2), inclusive (BMI=weight/height^2)
- Participant must be medically stable on the basis of the following: physical examination, vital signs (including blood pressure), and 12-lead electrocardiogram (ECG) performed at screening and baseline
Exclusion Criteria:
- Has a recent (last 3 months) history of, or current signs and symptoms of, severe renal insufficiency (creatinine clearance [CrCl] less than [<] 30 milliliter per minute [mL/min]); clinically significant or unstable cardiovascular, respiratory, gastrointestinal, neurologic, hematologic, rheumatologic, immunologic or endocrine disorders. uncontrolled Type 1 or Type 2 diabetes mellitus
- Has a history of treatment-resistant MDD, defined as a lack of response to 2 or more adequate antidepressant treatments in the current episode, as indicated by no or minimal (<25% improvement in symptoms) when treated with an antidepressant of adequate dose (per MGH-ATRQ) and duration (at least 6 weeks)
- Has history or current diagnosis of a psychotic disorder, bipolar disorder, intellectual disability, autism spectrum disorder, borderline personality disorder, somatoform disorders
- Has a history of moderate to severe substance use disorder including alcohol use disorder according to DSM-5 criteria within 6 months before screening
- Has any significant primary sleep disorder, including but not limited to obstructive sleep apnea, restless leg syndrome, or parasomnias. Participants with insomnia disorder are allowed
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Seltorexant
Adult participants will receive seltorexant once daily from Day 1-7 and together with matching placebo from Day 8 till Day 182. Elderly participants will receive seltorexant once daily from Day 1-3 and together with matching placebo from Day 4 till Day 182. |
Participants will receive seltorexant over-encapsulated tablet orally. Participants will receive placebo over-encapsulated tablet matching to seltorexant orally. |
|
Comparador activo: Quetiapine Extended-Release (XR)
Adult participants will receive quetiapine XR once daily from Day 1-2, followed by an increase in dose from Day 3-7, and from Day 8-14 together with matching placebo. After Day 14, quetiapine XR twice daily from Day 14 till Day 182. Elderly participants will receive quetiapine XR once daily from Day 1-3 and twice from Day 4-7, followed by an increase in dose once daily from Day 8-14 together with matching placebo. After Day 14 till Day 182, quetiapine XR will be adjusted by investigator based on the participant's clinical response and tolerability. |
Participants will receive quetiapine XR capsule orally. Participants will receive placebo capsule matching to quetiapine XR orally. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Percentage of Participants Who Achieved Response (Greater Than or Equal to [>=50] Percent Improvement in Montgomery-Asberg Depression Rating Scale [MADRS] Total Score From Baseline) at Week 26
Periodo de tiempo: Week 26
|
Percentage of participants who achieved response at Week 26 was reported. Responders were defined as participants with >= 50 percent (%) improvement in the MADRS total score from baseline. MADRS was a clinician-administered scale designed to measure depression severity and detected changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition. |
Week 26
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change From Baseline to Week 26 in Weight
Periodo de tiempo: Baseline (Day 1) and Week 26
|
Change from baseline to Week 26 in weight was reported. |
Baseline (Day 1) and Week 26
|
|
Time to Potentially Treatment Related Discontinuation of Study Drug
Periodo de tiempo: From first dose of study drug (Day 1) up to Week 30
|
Time to potentially treatment related discontinuation of study drug was reported. Time to discontinuation of study drug was defined as the number of days from the first dose of study drug to the last dose of study drug. Potentially treatment related discontinuation of study drug was defined as all study drug discontinuations excluding the potentially non-treatment related discontinuations (such as, loss of insurance for antidepressant therapy, movement/travel out of the area, change of work-schedule being unable to accommodate visit schedule, family circumstances, site terminated by sponsor, study terminated by sponsor). Kaplan-Meier estimate was used. |
From first dose of study drug (Day 1) up to Week 30
|
|
Change From Baseline to Week 26 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
Periodo de tiempo: Baseline (Day 1) and Week 26
|
Change from baseline to Week 26 in MADRS total score were reported. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition. |
Baseline (Day 1) and Week 26
|
|
Change From Baseline to Week 26 in MADRS-6 Total Score
Periodo de tiempo: Baseline (Day 1) and Week 26
|
Change from baseline to Week 26 in MADRS-6 total score was reported. The MADRS-6 scale was a clinician-administered questionnaire used to measure the severity of MDD symptoms. The MADRS-6 scale was a subset of the MADRS-10 scale, comprised of the following individual questionnaire items: apparent sadness, reported sadness, inner tension, lassitude, inability to feel, and pessimistic thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms), the overall score ranged from 0 to 36, higher scores represented a more severe condition. |
Baseline (Day 1) and Week 26
|
|
Change From Baseline to Week 26 in the MADRS Without Sleep Item (MADRS-WOSI) Total Score
Periodo de tiempo: Baseline (Day 1) and Week 26
|
The MADRS was a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant treatment. MADRS-WOSI was defined as the full MADRS without the sleep item. The MADRS-WOSI scale consisted of 9 items (apparent sadness, reported sadness, inner tension, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts), each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS-WOSI total score was the sum of scores from individual question items, which ranged from 0 to 54, higher scores represented a more severe condition. Negative change in MADRS total score indicated improvement. |
Baseline (Day 1) and Week 26
|
|
Change From Baseline to Week 26 in Patient Health Questionnaire, 9-Item (PHQ-9) Total Score
Periodo de tiempo: Baseline (Day 1) and Week 26
|
Change from baseline to Week 26 in PHQ-9 total score was reported. The PHQ-9 is a 9-item, participant reported outcome measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the diagnostic and statistical manual of mental disorders-5th edition (DSM-5) major depressive disorder (MDD) criteria. Each item was rated on a 4 point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. Negative changes in PHQ-9 total score indicated improvement. |
Baseline (Day 1) and Week 26
|
|
Percentage of Participants With MADRS Total Score Less Than or Equal to (<=) 12 at Week 26
Periodo de tiempo: Week 26
|
Percentage of participants with MADRS total score <=12 at Week 26 was reported. A participant was defined as a remitter at a given time point if the MADRS total score was <=12 at that time point. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition. |
Week 26
|
|
Percentage of Participants With a >=50 Percent Improvement in MADRS Total Score and MADRS <=18 at Week 26
Periodo de tiempo: Week 26
|
Percentage of participants with a >=50 percent improvement in MADRS total score and MADRS <=18 at Week 26 was reported. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition. |
Week 26
|
|
Percentage of Participants With >=7 Percent Weight Increase From Baseline at Week 26
Periodo de tiempo: Week 26
|
Percentage of participants with >=7 percent weight increase from baseline at Week 26 was reported. |
Week 26
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- CR108810
- 42847922MDD3005 (Otro identificador: Janssen Research & Development, LLC)
- 2020-000341-14 (Número EudraCT)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical- trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) project site at yoda.yale.edu
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .